Literature DB >> 29908151

Vaccination with a CD4+ and CD8+ T-cell epitopes-based recombinant chimeric protein derived from Leishmania infantum proteins confers protective immunity against visceral leishmaniasis.

Daniel S Dias1, Patrícia A F Ribeiro1, Vívian T Martins1, Daniela P Lage1, Lourena E Costa1, Miguel A Chávez-Fumagalli1, Fernanda F Ramos1, Thaís T O Santos1, Fernanda Ludolf1, Jamil S Oliveira2, Tiago A O Mendes3, Eduardo S Silva4, Alexsandro S Galdino4, Mariana C Duarte5, Bruno M Roatt6, Daniel Menezes-Souza5, Antonio L Teixeira7, Eduardo A F Coelho8.   

Abstract

Vaccination seems to be the best approach to control visceral leishmaniasis (VL). Resistance against infection is based on the development of a Th1 immune response characterized by the production of interferons-γ (IFN-γ), interleukin-12 (IL-12), granulocyte-macrophage-colony-stimulating factor (GM-CSF), and tumor necrosis factor-α (TNF-α), among others. A number of antigens have been tested as potential targets against the disease; few of them are able to stimulate human immune cells. In the present study, 1 prediction of MHC class I and II molecules-specific epitopes in the amino acid sequences of 3 Leishmania proteins: 1 hypothetical, prohibitin, and small glutamine-rich tetratricopeptide repeat-containing proteins, was performed using bioinformatics tools, and a T-cell epitopes-based recombinant chimeric protein was constructed, synthetized and purified to be evaluated in invitro and in vivo experiments. The purified protein was tested regarding its immunogenicity in peripheral blood mononuclear cells (PBMCs) from healthy subjects and VL patients, as well as to its immunogenicity and protective efficacy in a murine model against Leishmania infantum infection. Results showed a Th1 response based on high IFN-γ and low IL-10 levels derived from in chimera-stimulated PBMCs in both healthy subjects and VL patients. In addition, chimera and/or saponin-immunized mice presented significantly lower parasite burden in distinct evaluated organs, when compared to the controls, besides higher levels of IFN-γ, IL-2, IL-12, and GM-CSF, and an IgG2a isotype-based humoral response. In addition, the CD4+ and CD8+ T-cell subtypes contributed to IFN-γ production in the protected animals. The results showed the immunogenicity in human cells and the protective efficacy against L. infantum in a murine model, and well indicate that this recombinant chimera can be considered as a promising strategy to be used against human disease.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29908151     DOI: 10.1016/j.trsl.2018.05.001

Source DB:  PubMed          Journal:  Transl Res        ISSN: 1878-1810            Impact factor:   7.012


  9 in total

1.  A candidate vaccine for human visceral leishmaniasis based on a specific T cell epitope-containing chimeric protein protects mice against Leishmania infantum infection.

Authors:  Daniela P Lage; Patrícia A F Ribeiro; Daniel S Dias; Débora V C Mendonça; Fernanda F Ramos; Lívia M Carvalho; Daysiane de Oliveira; Bethina T Steiner; Vívian T Martins; Luísa Perin; Amanda S Machado; Thaís T O Santos; Grasiele S V Tavares; João A Oliveira-da-Silva; Jamil S Oliveira; Bruno M Roatt; Ricardo A Machado-de-Ávila; Antônio L Teixeira; Maria V Humbert; Eduardo A F Coelho; Myron Christodoulides
Journal:  NPJ Vaccines       Date:  2020-08-13       Impact factor: 7.344

2.  Computational tools for modern vaccine development.

Authors:  Andaleeb Sajid; Yogendra Singh; Pratyoosh Shukla
Journal:  Hum Vaccin Immunother       Date:  2019-12-18       Impact factor: 3.452

3.  Partial protection with a chimeric tetraspanin-leucine aminopeptidase subunit vaccine against Opisthorchis viverrini infection in hamsters.

Authors:  Luyen Thi Phung; Sujittra Chaiyadet; Nuttanan Hongsrichan; Javier Sotillo; Hang Dinh Thi Dieu; Canh Quang Tran; Paul J Brindley; Alex Loukas; Thewarach Laha
Journal:  Acta Trop       Date:  2020-01-25       Impact factor: 3.112

4.  A clioquinol-containing Pluronic® F127 polymeric micelle system is effective in the treatment of visceral leishmaniasis in a murine model.

Authors:  Grasiele S V Tavares; Débora V C Mendonça; Isabela A G Pereira; João A Oliveira-da-Silva; Fernanda F Ramos; Daniela P Lage; Amanda S Machado; Lívia M Carvalho; Thiago A R Reis; Luísa Perin; Ana Maria R S Carvalho; Flaviano M Ottoni; Fernanda Ludolf; Camila S Freitas; Raquel S Bandeira; Alessandra M Silva; Miguel A Chávez-Fumagalli; Mariana C Duarte; Daniel Menezes-Souza; Ricardo J Alves; Bruno M Roatt; Eduardo A F Coelho
Journal:  Parasite       Date:  2020-04-30       Impact factor: 3.000

5.  A candidate vaccine for human visceral leishmaniasis based on a specific T cell epitope-containing chimeric protein protects mice against Leishmania infantum infection.

Authors:  Daniela P Lage; Patrícia A F Ribeiro; Daniel S Dias; Débora V C Mendonça; Fernanda F Ramos; Lívia M Carvalho; Daysiane de Oliveira; Bethina T Steiner; Vívian T Martins; Luísa Perin; Amanda S Machado; Thaís T O Santos; Grasiele S V Tavares; João A Oliveira-da-Silva; Jamil S Oliveira; Bruno M Roatt; Ricardo A Machado-de-Ávila; Antônio L Teixeira; Maria V Humbert; Eduardo A F Coelho; Myron Christodoulides
Journal:  NPJ Vaccines       Date:  2020-08-13       Impact factor: 7.344

6.  A Recombinant Chimeric Protein-Based Vaccine Containing T-Cell Epitopes from Amastigote Proteins and Combined with Distinct Adjuvants, Induces Immunogenicity and Protection against Leishmania infantum Infection.

Authors:  Daniela P Lage; Danniele L Vale; Flávia P Linhares; Camila S Freitas; Amanda S Machado; Jamille M O Cardoso; Daysiane de Oliveira; Nathália C Galvani; Marcelo P de Oliveira; João A Oliveira-da-Silva; Fernanda F Ramos; Grasiele S V Tavares; Fernanda Ludolf; Raquel S Bandeira; Isabela A G Pereira; Miguel A Chávez-Fumagalli; Bruno M Roatt; Ricardo A Machado-de-Ávila; Myron Christodoulides; Eduardo A F Coelho; Vívian T Martins
Journal:  Vaccines (Basel)       Date:  2022-07-19

7.  Liposomal Formulation of ChimeraT, a Multiple T-Cell Epitope-Containing Recombinant Protein, Is a Candidate Vaccine for Human Visceral Leishmaniasis.

Authors:  Daniela P Lage; Patrícia A F Ribeiro; Daniel S Dias; Débora V C Mendonça; Fernanda F Ramos; Lívia M Carvalho; Bethina T Steiner; Grasiele S V Tavares; Vívian T Martins; Amanda S Machado; João A Oliveira-da-Silva; Thaís T O Santos; Camila S Freitas; Jamil S Oliveira; Bruno M Roatt; Ricardo A Machado-de-Ávila; Maria V Humbert; Myron Christodoulides; Eduardo A F Coelho
Journal:  Vaccines (Basel)       Date:  2020-06-09

8.  An immunoinformatic approach driven by experimental proteomics: in silico design of a subunit candidate vaccine targeting secretory proteins of Leishmania donovani amastigotes.

Authors:  Md Anik Ashfaq Khan; Jenifar Quaiyum Ami; Khaledul Faisal; Rajashree Chowdhury; Prakash Ghosh; Faria Hossain; Ahmed Abd El Wahed; Dinesh Mondal
Journal:  Parasit Vectors       Date:  2020-04-15       Impact factor: 3.876

9.  Design of multi-epitope peptides containing HLA class-I and class-II-restricted epitopes derived from immunogenic Leishmania proteins, and evaluation of CD4+ and CD8+ T cell responses induced in cured cutaneous leishmaniasis subjects.

Authors:  Sarra Hamrouni; Rachel Bras-Gonçalves; Abdelhamid Kidar; Karim Aoun; Rym Chamakh-Ayari; Elodie Petitdidier; Yasmine Messaoudi; Julie Pagniez; Jean-Loup Lemesre; Amel Meddeb-Garnaoui
Journal:  PLoS Negl Trop Dis       Date:  2020-03-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.